Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.57 |
| ▸ | PPARG | P37231 | 10/20 | 0.57 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 5/20 | 0.50 |
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541324 | 1.00 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL316084 | 1.00 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL13489723 | 1.00 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL5351802 | 1.00 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL7423487 | 0.94 | PPARA (0.55) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL22636123 | 0.94 | CYP1A2 (0.55) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL22381014 | 0.94 | PPARA (0.55) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL22636121 | 0.94 | CYP1A2 (0.55) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL12660176 | 0.94 | PPARA (0.52) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL16289560 | 0.94 | PPARA (0.55) | PPARAPPARGPPARDCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4444728-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | Pretzel Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107487-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230114304-A1 | DEPALMITOYLATING COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | disclosed |
| US-20210128516-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | NOVARTIS AG (CH) | 2021-05-06 | — | — | US | disclosed |
| WO-2021030703-A1 | DEPALMITOYLATING COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. | 2018-07-12 | — | — | US | disclosed |
| EP-3332811-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING COVALENTLY ATTACHED CAMPTOTHECIN | Cerulean Pharma Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9951001-B2 | Hepatoprotectant acetaminophen mutual prodrugs | ACORDA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170369651-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | INSERT THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| EP-2277551-A2 | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto | Cerulean Pharma Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009143299-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143299-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090215166-A1 | Cationic Polymer for Transporting Nucleic Acids in Cells | UNIVERSITAT REGENSBURG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20080226503-A1 | Method for selective detection of peptides using molecularly imprinted sensors | TAI DAR-FU | 2008-09-18 | — | — | US | disclosed |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7270808-B2 | Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity | INSERT THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-0764149-B1 | NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE POULENC RORER SA (FR) | 1999-01-20 | — | — | EP | disclosed |
| US-5861529-A | ANTICANCER AGENTS | RHONE-POULENC RORER S.A. (FR) | 1999-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | LONP1, NLN, ACAT1 | PPARA 2100/4885PPARG 1869/4885PPARD 2834/4885 |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | PPARA 3042/4885PPARG 2713/4885PPARD 3733/4885 |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | DDOST, DSC1, SI | PPARA 2719/4885PPARG 3037/4885PPARD 2514/4885 |
| US-20210128516-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | SDCBP, DDOST, CD47 | PPARA 3034/4885PPARG 3148/4885PPARD 3298/4885 |
| US-20230114304-A1 | DEPALMITOYLATING COMPOSITIONS AND THE USE THEREOF | LIPA, LCAT, SGMS2 | PPARA 803/4885PPARG 2046/4885PPARD 996/4885 |
| US-20170369651-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | SDCBP, DDOST, CD47 | PPARA 3034/4885PPARG 3148/4885PPARD 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.